Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy Volunteers

NCT02245269 | Completed Phase 1

• 1 other identifier: 1182.21
• Study Type: interventional
• Target: 23
• Locations: 0 countries
• Sites: N/A

Brief Summary

Study to determine the effects of combined tipranavir and ritonavir treatment (at steady-state) on the single-dose pharmacokinetics of atorvastatin, the effects of single-dose atorvastatin on the steady-state pharmacokinetics of tipranavir, and the effects of antacid on the pharmacokinetics of tipranavir

Conditions

Healthy

Outcome Measures

Primary Outcomes (4)

• Area under the plasma drug concentration-time curve from time zero to infinity of the analyte (AUC0-∞)

  up to day 22

• Maximum plasma concentration of the analyte (Cmax)

  up to day 22

• Drug concentration of the analyte in plasma at 12 hours after administration (Cp12h)

  up to day 22

• AUC0-12 hours of the analyte

  up to day 22

Secondary Outcomes (8)

• Oral clearance (CL/F)

  up to day 22

• Volume of distribution (V)

  up to day 22

• Time of maximum concentration (tmax)

  up to day 22

• Apparent terminal half life (t1/2)

  up to day 22

• Mean Residence Time (MRT)

  up to day 22

Study Arms (1)

TPV/r + Atorvastatin followed by TPV/r + antacid

EXPERIMENTAL

Day 1: first dose of ATV Day 8: single dose of TPV/r Day 13: single dose of TPV/r, followed by a single dose of Maalox Days 14-21: morning and evening doses of TPV/r on Day 20: second dose of ATV

Drug: Tipranavir; Drug: Ritonavir; Drug: Atorvastatin; Drug: Maalox

Interventions

Tipranavir DRUG

TPV/r + Atorvastatin followed by TPV/r + antacid

Ritonavir DRUG

TPV/r + Atorvastatin followed by TPV/r + antacid

Atorvastatin DRUG

TPV/r + Atorvastatin followed by TPV/r + antacid

Maalox DRUG

Aluminum Hydroxide; Magnesium Hydroxide; Simethicone

TPV/r + Atorvastatin followed by TPV/r + antacid

Eligibility Criteria

• Age: 18 Years - 22 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Male and female subjects between 18 and 60 years of age inclusive
• A Body Mass Index (BMI) between 18 and 29 kg/m2
• Signed informed consent prior to trial participation
• Ability to swallow numerous study medications
• Acceptable laboratory values that indicate adequate baseline organ function are required at the time of screening. Laboratory values are considered to be acceptable if severity is less than or equal to Grade 1, based on the AIDS Clinical Trials Group Grading Scale
• Acceptable medical history, physical examination and ECG, and chest X-ray (if not conducted within the last 12 months) are required prior to entering the treatment phase of the study
• Willingness to abstain from alcohol starting 2 days prior to any administration study drug up to the end of the study. Red wine must not be ingested within 5 days prior to treatment and throughout the study
• Willingness to abstain from the following starting 10 days prior to any administration of study drug up until the end of the study:
• Grapefruit or grapefruit juice or products containing grapefruit juice
• Willingness to abstain from ingesting Seville oranges, garlic supplements, St. John's Wort, or Milk Thistle, within 5 days of treatment and for the duration of the study
• Willingness to abstain from methylxanthine-containing drinks or foods (coffee, tea, cola, energy drinks, chocolate, etc.) within 72 hours of each pharmacokinetic (PK) sampling day and until after the last sample from each of the intensive sampling days is collected
• Willingness to abstain from over the counter herbal medications for the duration of the study
• Willingness to abstain from vigorous physical exercise during PK Days
• Reasonable probability for completion of the study

You may not qualify if:

• Female subjects who are of reproductive potential who:
• Have positive serum β-human chorionic gonadotropin at Visit 1, or on Day 0
• Have not been using a barrier contraceptive method for at least 3 months prior to Day 0 (Visit 2)
• Are not willing to use a reliable method of barrier contraception (such as diaphragm or condoms), during the trial and 30 days after completion/termination
• Are breast-feeding
• Use of any pharmacological contraceptive (including oral, patch or injectable contraceptives) for 1 month prior to study initiation and for the duration of the study
• Use of hormone replacement therapy for 1 month prior to study initiation and for the duration of the study
• Participation in another trial with an investigational medicine within 60 days prior to Day 0 (Visit 2)
• Use of any medication listed in the protocol within 30 days prior to Day 0 (Visit 2)
• Administration of antibiotics within 10 days prior to Day 0 (Visit 2) or during the trial
• History of acute illness within the past sixty (60) days. Subjects will be excluded for these disorders greater than sixty days if, in the opinion of the investigator, the subject does not qualify as a healthy volunteer
• Have serological evidence of Hepatitis B or C Virus
• Have serological evidence of exposure to HIV
• Recent history of alcohol or substance abuse (within 6 months of study period)
• Smokers who smoke greater than 10 cigarettes or 3 cigars or 3 pipes per day; inability to refrain from smoking during the trial

Sponsors & Collaborators

• Boehringer Ingelheim: lead

MeSH Terms

Interventions

tipranavir; Ritonavir; Atorvastatin; aluminum hydroxide, magnesium hydroxide, drug combination

Intervention Hierarchy (Ancestors)

Thiazoles; Sulfur Compounds; Organic Chemicals; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Pyrroles; Heptanoic Acids; Fatty Acids; Lipids

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 18, 2014
• First Posted: September 19, 2014
• Study Start: July 1, 2003
• Primary Completion: October 1, 2003
• Last Updated: September 19, 2014

Record last verified: 2014-09